Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06618924
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-09-16
Brief Title:
Digital Modeling of Thoracic CT and Pulmonary Fibrosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Quantitative Multi-compartment Study by Thoracic CT Scanning in Progressive Pulmonary Fibrosis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MLQ-CT
Brief Summary:
Currently to our knowledge there is little data on the combination of tools based on a similar concept to understand and evaluate ILDs It is expected that this portfolio of multi-tool software implemented in radiology departments applied to routine thoracic TDM will provide additional qualitative and quantitative information in real time that will be of great help for diagnosis prognosis prediction and treatment decision-making in ILDs
Detailed Description:
Thoracic CT scanning has revolutionized the definition of interstitial lung diseases ILDs some of which inexorably progress to pulmonary fibrosis eg progressive pulmonary fibrosis or PPF leading to early death or lung transplantation Over the past decade various treatments have shown effectiveness in slowing this fibrotic progression but it is still not possible to define which patients might personally benefit from these treatments and when to prescribe them Two major questions remain
Why do some patients develop fibrosis despite seemingly appropriate treatment What are the mechanisms driving this fibrotic progression Hence there is a great need to define biomarkers to answer these questions particularly in the early phase For more than 5 years within a consortium including Avicenne Hospital APHP 93000 Bobigny INSERM Unit 1272 Sorbonne Paris North University and two partner laboratories Mines Telecom and Ecole Polytechnique-INRIA both belonging to the Institut Polytechnique we have been developing the applications of artificial intelligence AI to lung imaging extracting static and dynamic data from thoracic CT scans to aid in the diagnosis and follow-up of patients without additional examinations beyond standard care Our projectamp39s objective is to identify patients at risk of progressive and irreversible fibrosis and those who could respond to antifibrotic treatments by developing the identification of qualitative and quantitative biomarkers from the numerical modeling of routine thoracic CT scans
Our program which has just been funded in 2023 by the National Research Agency ANR 2023 MLQ-CT aims to
Develop a portfolio of software tools whose use should be facilitated in the hospital sector based on research prototypes already built and tested in our consortium for several years
Apply them to a set of interstitial lung diseases ILDs known to be at risk of fibrotic progression
Transfer these tools to the radiology department of Avicenne Hospital APHP Conduct real-time experimentation between two pulmonology departments one at Avicenne Hospital APHP and the other at Caen University Hospital and the radiology department of Avicenne Hospital APHP to validate the feasibility of using such biomarkers
Why do some patients develop fibrosis despite seemingly appropriate treatment What are the mechanisms driving this fibrotic progression Hence there is a great need to define biomarkers to answer these questions particularly in the early phase For more than 5 years within a consortium including Avicenne Hospital APHP 93000 Bobigny INSERM Unit 1272 Sorbonne Paris North University and two partner laboratories Mines Telecom and Ecole Polytechnique-INRIA both belonging to the Institut Polytechnique we have been developing the applications of artificial intelligence AI to lung imaging extracting static and dynamic data from thoracic CT scans to aid in the diagnosis and follow-up of patients without additional examinations beyond standard care Our projectamp39s objective is to identify patients at risk of progressive and irreversible fibrosis and those who could respond to antifibrotic treatments by developing the identification of qualitative and quantitative biomarkers from the numerical modeling of routine thoracic CT scans
Our program which has just been funded in 2023 by the National Research Agency ANR 2023 MLQ-CT aims to
Develop a portfolio of software tools whose use should be facilitated in the hospital sector based on research prototypes already built and tested in our consortium for several years
Apply them to a set of interstitial lung diseases ILDs known to be at risk of fibrotic progression
Transfer these tools to the radiology department of Avicenne Hospital APHP Conduct real-time experimentation between two pulmonology departments one at Avicenne Hospital APHP and the other at Caen University Hospital and the radiology department of Avicenne Hospital APHP to validate the feasibility of using such biomarkers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None